Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients

Backgrounds and Purpose Concurrent non-alcoholic fatty liver disease (NAFLD) in chronic hepatitis B (CHB) patients is a frequent and increasingly concerning problem because of the NAFLD pandemic. Admittedly, NAFLD can progress to non-alcoholic steatohepatitis (NASH) and severe fibrosis. Direct evidence of the fibrotic effect of NAFLD or NASH in chronic hepatitis B virus (HBV) infection remains lacking. We aimed to reveal the influence of concurrent histologically proven fatty liver diseases in fibrogenesis with chronic HBV infection. Methods We performed a retrospective cross-sectional study on a liver biopsy population of CHB patients without excessive alcohol intake to evaluate the prevalence of concurrent histologically proven NAFLD or NASH according to the fatty liver inhibition of progression (FLIP) algorithm and its association with the liver fibrosis stage. Results Among 1,081 CHB patients, concurrent NAFLD was found in 404 patients (37.4%), among whom 24.0% (97/404) have NASH. The presence of NASH was an independent predictor of significant fibrosis (odds ratio (OR), 2.53; 95% CI, 1.52–4.21; p < 0.001) and severe fibrosis (OR, 1.83; 95% CI, 1.09–3.09; p = 0.023) in all patients, as well as in patients with normal alanine aminotransferase (ALT) (predicting significant fibrosis, OR, 2.86, 95% CI, 1.34–6.10; p = 0.007). The presence of lobular inflammation (p < 0.001) or presence of cytological ballooning (p < 0.001), rather than presence of steatosis (p = 0.419), was related with severity of fibrosis in Spearman’s correlation analysis. Conclusions Concurrent NAFLD is common in CHB patients, and NASH is an independent risk factor potentiating significant fibrosis by 2.53-fold and severe fibrosis by 1.83-fold. While coping with chronic HBV infection, routine assessment of co-existing NAFLD or NASH is also important.

[1]  T. Luedde,et al.  An elevated FIB-4 score predicts liver cancer development: a longitudinal analysis from 29,999 NAFLD patients: Reply to: "EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis- 2021 update". , 2021, Journal of hepatology.

[2]  M. Friedrich-Rust,et al.  Easl Clinical Practice Guidelines (Cpgs) On Non-Invasive Tests For Evaluation Of Liver Disease Severity And Prognosis- 2020 Update. , 2021, Journal of hepatology.

[3]  Xing Gao,et al.  Disruption of Plin5 degradation by CMA causes lipid homeostasis imbalance in NAFLD , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[4]  H. Janssen,et al.  Nonalcoholic Steatohepatitis Is Associated With Liver‐Related Outcomes and All‐Cause Mortality in Chronic Hepatitis B , 2020, Hepatology.

[5]  Yuanwen Chen,et al.  Chronic hepatitis B and non‐alcoholic fatty liver disease: Conspirators or competitors? , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[6]  P. Bedossa,et al.  Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease. , 2019, Journal of hepatology.

[7]  Q. Pan,et al.  Moderate to severe hepatic steatosis leads to overestimation of liver stiffness measurement in chronic hepatitis B patients without significant fibrosis , 2019, Alimentary pharmacology & therapeutics.

[8]  P. Popovič,et al.  Prevalence of liver steatosis in patients with chronic intestinal failure , 2018, Clinical Nutrition.

[9]  J. Gong,et al.  Current but not past hepatitis B virus infection is associated with a decreased risk of nonalcoholic fatty liver disease in the Chinese population: A case‐control study with propensity score analysis , 2018, Journal of viral hepatitis.

[10]  S. Alavian,et al.  Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. , 2018, The lancet. Gastroenterology & hepatology.

[11]  M. Yuen,et al.  Inverse relationship between hepatic steatosis and hepatitis B viremia: Results of a large case‐control study , 2018, Journal of viral hepatitis.

[12]  Q. Xie,et al.  Algorithm of Golgi protein 73 and liver stiffness accurately diagnoses significant fibrosis in chronic HBV infection , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[13]  H. Li,et al.  Assessment of serum Golgi protein 73 as a biomarker for the diagnosis of significant fibrosis in patients with chronic HBV infection , 2017, Journal of viral hepatitis.

[14]  Thomas Berg,et al.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. , 2017, Journal of hepatology.

[15]  N. Pausawasdi,et al.  The prevalence of steatohepatitis in chronic hepatitis B patients and its impact on disease severity and treatment response , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[16]  Herbert Tilg,et al.  Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases , 2017, Gut.

[17]  V. Wong,et al.  Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B , 2016, Hepatology.

[18]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[19]  A. Diehl,et al.  Pathogenesis of Nonalcoholic Steatohepatitis. , 2016, Gastroenterology.

[20]  P. Bedossa.  Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease , 2014, Hepatology.

[21]  Rohit Loomba,et al.  The global NAFLD epidemic , 2013, Nature Reviews Gastroenterology &Hepatology.

[22]  Lungen Lu,et al.  Predictors of hepatic steatosis in HBeAg-negative chronic hepatitis B patients and their diagnostic values in hepatic fibrosis , 2010, International journal of medical sciences.

[23]  H. Mani,et al.  Liver biopsy findings in chronic hepatitis B , 2009, Hepatology.

[24]  Kook Hwan Kim,et al.  Hepatitis B virus X protein induces lipogenic transcription factor SREBP1 and fatty acid synthase through the activation of nuclear receptor LXRalpha. , 2008, The Biochemical journal.

[25]  V. Wong,et al.  Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B , 2008, Gut.

[26]  Lai Wei,et al.  Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors , 2008, Journal of gastroenterology and hepatology.

[27]  Z. Younossi,et al.  Impact of non‐alcoholic fatty liver disease on chronic hepatitis B , 2007, Liver international : official journal of the International Association for the Study of the Liver.

[28]  Kook Hwan Kim,et al.  Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma. , 2007, Gastroenterology.

[29]  D. Dimitropoulou,et al.  Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis , 2006, European journal of gastroenterology & hepatology.

[30]  H. Kumada,et al.  [Chronic hepatitis B]. , 2001, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology.

[31]  P. Scheuer,et al.  Classification of chronic viral hepatitis: a need for reassessment. , 1991, Journal of hepatology.

[32]  Guías de Práctica Clínica.  European Association for the Study of the Liver , 1971 .

[33]  L. Henry,et al.  NAFLD AND NASH: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018 .

[34]  R. Mikolajczyk,et al.  Time trends of chronic HBV infection over prior decades - A global analysis. , 2017, Journal of hepatology.

[35]  For Personal Use. Only Reproduce with Permission from the Lancet , 2022 .